Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 20% Intralipid Clear all

Conditions: Diabetes, Hypertension, Obesity
Interventions: Intralipid 20%, Normal Saline, Oral fat load; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Abscess
Interventions: Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy; Procedure · Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cholestasis
Interventions: Intralipid 20% I.V. Fat Emulsion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 1 Year
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more

Conditions: Parenteral Nutrition
Interventions: ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Abscess
Interventions: Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage; Drug · Device · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Hypertension, Diabetes
Interventions: Salsalate, Carvedilol, Placebo, Intralipid 20%; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anesthesia, Local
Interventions: Lidocaine 2%, Lidocaine 1%, Bupivacaine 0.25%, Bupivacaine 0.5%, Intralipid, 20% Intravenous, Saline intravenously, Saline; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertriglyceridemia, Hyperglycemia
Interventions: Intravenous Fat Emulsions; Drug
Lead sponsor: OSF Healthcare System; Other
Eligibility: 1 Day to 2 Days
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Neoplasms
Interventions: MST-997; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Nashville, Tennessee

Conditions: Cholestasis, Prematurity, Gastroschisis, Intestinal Atresia, Necrotizing Enterocolitis
Interventions: Parenteral Nutrition; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: Up to 7 Days
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertriglyceridemia
Interventions: Liposyn III 20% (lipid infusion), Intralipid 20% (lipid infusion); Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 2 Days to 10 Days
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: 20% lipid infusion, glycerol; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Abscess
Interventions: Methylene Blue, 20% I.V. Fat Emulsion, Insertion of optical fiber, Laser illumination, 5 minutes, Laser illumination, 10 minutes, Laser illumination, 15 minutes, Laser illumination, 20 minutes, Laser illumination, 25 minutes, Laser illumination, 30 minutes, Optical spectroscopy measurement; Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: Fat Emulsion 2%, Fat Emulsion 20%; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: East Orange, New Jersey

Conditions: Endothelial Dysfunction, Hypertension
Interventions: Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load; Drug · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Dyspnea, Hypertension, Acute Heart Failure
Interventions: Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label); Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more

Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Interventions: Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: PreDiabetes
Interventions: Intralipid and heparin, Saline; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cholestasis of Parenteral Nutrition
Interventions: Smoflipid 20% Lipid Emulsion for Injection, Intralipid, 20% Intravenous Emulsion; Drug
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Mellitus, Type 2
Interventions: Intralipid 20%, Glucose infusion; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions: Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%; Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 0 Weeks and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more

Conditions: Inflammation, Insulin Resistance
Interventions: 20% Intralipid; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Obesity, Leptin Resistance
Interventions: Saline, Intralipid, Water, oral fat, Heparin; Drug · Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
Interventions: Omegaven™; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

FFA Hypertension and Inflammation in Lean and Obese Subjects

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Intralipid® 20% for Reversal of Local Anesthetics

Intravenous Fat Emulsions and Premature Infants

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants

Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic

Training Effects on Skeletal Muscle Fatty Acid Metabolism

Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities

A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)

FFA-Induced Hypertension and Endothelial Dysfunction

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

Fatty Acid Oxidation Defects and Insulin Sensitivity

Insulin and Insulin Pulses During Fasting

Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Mechanisms of Insulin Resistance in Humans

Effect of Increased Free Fatty Acids on Leptin Function

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis